Advertisement

Topics

Companies Related to "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" [Most Relevant Company Matches] RSS

18:19 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Empagliflozin 10773 Patients With Type Diabetes" Companies 1–25 of 5,800+

Extremely Relevant

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a propri...


Relevant

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...

Team Type 1 Foundation

Established in 2013, the Team Type 1 Foundation is a nonprofit organization pursuing a mission of education, empowerment and equal access to medicine for everyone affected by diabetes. Collaborating with governments, healthcare professionals, diabetes experts and individuals living with diabetes around the world, the Team Type 1 Foundation is bridging the ...


Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

Creative Peptides develops pharmaceutical products

Creative Peptides develops pharmaceutical products based on C-peptide Our research will significantly improve on the treatment of long-term complications of type 1 diabetes. Complications of type 1 diabetes are currently not effectively and safely treatable and cause great suffering in afflicted patients as well as vast costs to society

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

BioMedical Research Models Incorporated (BRM)

Biomedical Research Models, Inc. (BRM) is a full service Contract Research Organization. We specialize in value added studies using our propriety model systems. BRM conducts studies on the efficacy of new drugs to improve Type 1 and Type 2 diabetes, diabetic complications, cancer, rheumatoid arthritis and auto-immune disease.

The T1D Exchange

The T1D Exchange is a unique platform for collaborative data collection and sharing that consists of three overlapping components: a clinic-based registry with clinical, biological and other real-life information from individuals with type 1 diabetes, a registry that is coordinated through a network of clinical centers and an interactive online community f...

Metabolex Incorporated

Metabolex discovers and develops new drugs for type 2 diabetes, bringing to the market novel drugs that address the molecular mechanisms underlying the disease. Such therapeutics are needed to more effectively control patients' blood glucose levels and impede progression of diabetes and its complications.Metabolex has a team of dedicated experts and a robust technology base in diabetes biology and...

DreaMed Diabetes

DreaMed Diabetes was established in 2014 to develop and commercialize diabetes treatment and management solutions. Its flagship product, GlucoSitter™, is a closed-loop insulin delivery system for patients with type 1 and type 2 diabetes. Additional development programs include insulin-treatment-profiling systems for diabetic clinics, patient decision-...

ImmunoMolecular Therapeutics

IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell fun...

Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes and related metabolic diseases. This new approach seeks to improve the efficacy of treatment and free patients from the adverse side effects of current treatments, including edema and weight gain.

Team Type 1

Based in Atlanta, GA, Team Type 1 began as a grassroots initiative to motivate people to take control of their diabetes using cycling as a platform. It grew to become a world-class athletic program for all athletes with diabetes, including a professional men's cycling team, poised to compete at the 2012 Tour de France. Today, it is a global sports organiza...

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Diamyd Medical AB (publ)

The purpose of the GAD65-based diabetes therapy Diamyd(R) is to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby preserving the body's capacity to regulate blood sugar. This reduces the risk for both acute and long term diabetes complications significantly.

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Point Therapeutics

Point Therapeutics, Inc is a Boston-based biopharmaceutical company dedicated to developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. DPPs are enzymes that appear to regulate several different physiological processes including those involved in tumor growth and host responses to cancer, type 2 diabetes, and immune responses to v...

DiObex

DiObex, Inc., a clinical-stage company based in San Francisco, is developing unique, first-in-class therapies for the critically under-served metabolic disease market. Our pipeline products address the markets for the treatment of type 1 diabetes, type 2 diabetes and its co-morbidities such as hypertension, dyslipidemia and visceral adiposity (often referred to collectively as “metabolic syndrom...

Exsulin Corporation

Based in Minneapolis, Exsulin Corporation has global rights to and pioneered the development of an experimental approach for the treatment of Type 1 and Type 2 diabetes with the goal of affecting the future of diabetes care and providing significant cost savings within the healthcare system. Exsulin has worked with leading research labs in multiple countries to develop the technology that has led ...

Novocell, Inc.

Novocell is a preclinical therapeutic company focused on diabetes. Our therapy is based on the encapsulation and implantation of pancreatic beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients. Our goal is that Pro-Islet-1 can free both Type 1 and Type 2 diabetic patients from insulin dependence on a long term basis, while reducing or eliminating hy...

DiabetesMine.com

DiabetesMine.com is an information resource and a community networking place for people affected by diabetes. Its creator, Amy Tenderich, is a journalist who lives with Type 1 diabetes herself, and shares an unusual “cynically optimistic” view of the trials of living with this condition. She speaks creatively and from the heart — to people with dia...

Dance Pharma

Dance is a San Francisco based, global company focused exclusively on creating a line of small, patient friendly, pain-less, low cost insulin inhalers for the world diabetes market. In addition to providing inhaled insulin to those who have become insulin dependent, the company also intends to enable introduction of insulin much earlier in the disease proc...


More From BioPortfolio on "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks